CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

[1]  E. Appella,et al.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Ohmori,et al.  Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. , 1993, The American journal of pathology.

[3]  Armen B. Shanafelt,et al.  The Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis (*) , 1995, The Journal of Biological Chemistry.

[4]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[5]  G. Stark,et al.  Characterization of β-R1, a Gene That Is Selectively Induced by Interferon β (IFN-β) Compared with IFN-α* , 1996, The Journal of Biological Chemistry.

[6]  J. Farber.  Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[7]  Yoshihiro Ohmori,et al.  Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κB* , 1997, The Journal of Biological Chemistry.

[8]  J. Demartino,et al.  Binding and Functional Properties of Recombinant and Endogenous CXCR3 Chemokine Receptors* , 1998, The Journal of Biological Chemistry.

[9]  J. Finke,et al.  The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. , 1998, Journal of immunology.

[10]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[11]  A. Luster,et al.  Structure and function of the murine chemokine receptor CXCR3 , 1999, European journal of immunology.

[12]  M. Burdick,et al.  Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10) , 2001, Cancer Immunology, Immunotherapy.

[13]  E. Kunkel,et al.  Rules of chemokine receptor association with T cell polarization in vivo. , 2001, The Journal of clinical investigation.

[14]  N. Netzer,et al.  Plasmid DNA Encoding IFN-γ-Inducible Protein 10 Redirects Antigen-Specific T Cell Polarization and Suppresses Experimental Autoimmune Encephalomyelitis1 , 2002, The Journal of Immunology.

[15]  W. Park,et al.  Induction of the chemokine receptor CXCR3 on TCR‐stimulated T cells: dependence on the release from persistent TCR‐triggering and requirement for IFN‐γ stimulation , 2002, European journal of immunology.

[16]  A. Feldman,et al.  Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.

[17]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[18]  T. Williams,et al.  CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 , 2003, European journal of immunology.

[19]  M. Huang,et al.  Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. , 2003, Human gene therapy.

[20]  Antonio Lanzavecchia,et al.  Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming , 2004, Nature Immunology.

[21]  M. Burdick,et al.  Identification and Partial Characterization of a Variant of Human CXCR3 Generated by Posttranscriptional Exon Skipping1 , 2004, The Journal of Immunology.

[22]  T. Manabe,et al.  Pivotal Role of CXCR3 in Melanoma Cell Metastasis to Lymph Nodes , 2004, Cancer Research.

[23]  Andrew D. Luster,et al.  Intracellular Domains of CXCR3 That Mediate CXCL9, CXCL10, and CXCL11 Function* , 2004, Journal of Biological Chemistry.

[24]  Andreas Radbruch,et al.  Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. , 2005, Blood.

[25]  P. Hensbergen,et al.  The CXCR3 Targeting Chemokine CXCL11 Has Potent Antitumor Activity In Vivo Involving Attraction of CD8+ T Lymphocytes But Not Inhibition of Angiogenesis , 2005, Journal of immunotherapy.

[26]  C. Brightling,et al.  The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. , 2005, American journal of respiratory and critical care medicine.

[27]  L. Álvarez-Vallina,et al.  Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth , 2005, Cancer Gene Therapy.

[28]  M. Burdick,et al.  CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.

[29]  Felix Eichinger,et al.  Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.

[30]  Kevin Wei,et al.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development , 2006, The Journal of experimental medicine.

[31]  A. Luster,et al.  Both CXCR3 and CXCL10/IFN-Inducible Protein 10 Are Required for Resistance to Primary Infection by Dengue Virus1 , 2006, The Journal of Immunology.

[32]  A. Llombart‐Bosch,et al.  CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors , 2006, Journal of Clinical Pathology.

[33]  L. Tian,et al.  Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma , 2006, Gene Therapy.

[34]  S. Xiong,et al.  Targeted in vivo expression of IFN‐γ‐inducible protein 10 induces specific antitumor activity , 2006 .

[35]  Michael G. Johnson,et al.  Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.

[36]  Xinrong Ma,et al.  Immune-mediated Modulation of Breast Cancer Growth and Metastasis by the Chemokine Mig (CXCL9) in a Murine Model , 2007, Journal of immunotherapy.

[37]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[38]  C. Qian,et al.  TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. , 2007, Blood.

[39]  T. Manabe,et al.  Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes , 2007, Oncogene.

[40]  R. Figlin,et al.  Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy , 2007, Journal of immunotherapy.

[41]  H. Weiner,et al.  A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells , 2007, Nature Immunology.

[42]  J. Finke,et al.  CXC Chemokine Ligand 9/Monokine Induced by IFN-γ Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors1 , 2007, The Journal of Immunology.

[43]  B. Shalmon,et al.  CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. , 2007, Cancer research.

[44]  B. Medoff,et al.  Development of a novel chemokine-mediated in vivo T cell recruitment assay. , 2008, Journal of immunological methods.

[45]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[46]  R. Langer,et al.  Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy , 2009, Breast Cancer Research and Treatment.

[47]  T. Means,et al.  CXCL9, but not CXCL10, promotes CXCR3-dependent immune-mediated kidney disease. , 2008, Journal of the American Society of Nephrology : JASN.

[48]  A. Cerwenka,et al.  Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. , 2008, Cancer research.

[49]  N. Matsumura,et al.  Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression , 2009, Modern Pathology.

[50]  David J. Miller,et al.  Role of Double-Stranded RNA Pattern Recognition Receptors in Rhinovirus-Induced Airway Epithelial Cell Responses1 , 2009, The Journal of Immunology.

[51]  E. Kleinerman,et al.  Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs , 2009, International journal of cancer.

[52]  P. Gimotty,et al.  CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model , 2009, Molecular Cancer Therapeutics.

[53]  D. Birnbaum,et al.  Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism , 2009, British Journal of Cancer.

[54]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[55]  H. Weiner,et al.  The Aryl hydrocarbon Receptor (AhR) interacts with c-Maf to promote the differentiation of IL-27-induced regulatory type 1 (TR1) cells , 2010, Nature Immunology.

[56]  S. Ward,et al.  Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes , 2011, Immunology.

[57]  Benyan Wu,et al.  Foxp3+IL‐17+ T cells promote development of cancer‐initiating cells in colorectal cancer , 2011, Journal of leukocyte biology.

[58]  O. Werlenius,et al.  Tumour‐loaded α‐type 1‐polarized Dendritic Cells from Patients with Chronic Lymphocytic Leukaemia Produce a Superior NK‐, NKT‐ and CD8+ T Cell‐attracting Chemokine Profile , 2011, Scandinavian journal of immunology.

[59]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[60]  C. Mackay,et al.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. , 2011, Cancer research.

[61]  M. Huang,et al.  Role of CXCR3 Ligands in IL-7/IL-7Rα-Fc–Mediated Antitumor Activity in Lung Cancer , 2011, Clinical Cancer Research.

[62]  I. Andrulis,et al.  Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry , 2012, Clinical Cancer Research.

[63]  M. Kiechle,et al.  Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer , 2012, Breast Cancer Research.

[64]  P. Hwu,et al.  PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. , 2012, Cancer research.

[65]  F. Mami-Chouaib,et al.  Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. , 2012, Cancer research.

[66]  A. Szabo,et al.  Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFN&bgr; secretion controlled differently by TLR3 and MDA5 , 2012, Melanoma research.

[67]  Xiao-ling Lu,et al.  A novel recombinant protein of IP10-EGFRvIIIscFv and CD8+ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice , 2013, Cancer Immunology, Immunotherapy.

[68]  Nina Daschil,et al.  Lapatinib and doxorubicin enhance the Stat1‐dependent antitumor immune response , 2013, European journal of immunology.

[69]  F. Marincola,et al.  Prediction of response to anticancer immunotherapy using gene signatures. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Jinxiang Han,et al.  miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration. , 2013, Biochemical and biophysical research communications.

[71]  R. Simon,et al.  CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 , 2013, British Journal of Cancer.

[72]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[74]  Dmitri I. Kotov,et al.  CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model , 2014, Immunology.

[75]  A. Nagler,et al.  Heparanase enhances myeloma progression via CXCL10 downregulation , 2014, Leukemia.

[76]  Xiao-ling Lu,et al.  Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model , 2014, Tumor Biology.

[77]  R. Alon,et al.  CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. , 2014, The Journal of clinical investigation.

[78]  J. Cerhan,et al.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. , 2015, Blood.

[79]  R. Weichselbaum,et al.  Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome , 2015, British Journal of Cancer.

[80]  J. Wolchok,et al.  Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.

[81]  S. Motoyama,et al.  CXCL10 Expression Status is Prognostic in Patients with Advanced Thoracic Esophageal Squamous Cell Carcinoma , 2016, Annals of Surgical Oncology.

[82]  Jiang Jian,et al.  CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity , 2015, Oncotarget.

[83]  Gang Wu,et al.  Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity , 2016, Oncoimmunology.

[84]  Chenggang Yang,et al.  CXCR3A contributes to the invasion and metastasis of gastric cancer cells. , 2016, Oncology reports.

[85]  M. Kiechle,et al.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer , 2016, British Journal of Cancer.

[86]  R. Dikshit,et al.  IL17 producing γδT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients , 2016, International journal of cancer.

[87]  V. Jala,et al.  Chemoattractant Receptors BLT1 and CXCR3 Regulate Antitumor Immunity by Facilitating CD8+ T Cell Migration into Tumors , 2016, The Journal of Immunology.

[88]  Z. Guo,et al.  CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy , 2015, Oncoimmunology.

[89]  Jun Yan,et al.  The chemokine CXCL9 expression is associated with better prognosis for colorectal carcinoma patients. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[90]  H. Ludwig,et al.  Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma , 2016, Leukemia & lymphoma.

[91]  Le Xu,et al.  Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma , 2016, Oncotarget.

[92]  Kyu-Sang Park,et al.  Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFkB activation. , 2016, Cytokine.

[93]  A. Casrouge,et al.  Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies , 2016, EMBO molecular medicine.

[94]  David A. Drew,et al.  Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. , 2016, Gastroenterology.

[95]  P. Hammerman,et al.  Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer , 2016, British Journal of Cancer.

[96]  K. Ott,et al.  Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer , 2017, Oncotarget.

[97]  D. Curiel,et al.  COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells , 2017, Proceedings of the National Academy of Sciences.

[98]  S. Hervás-Stubbs,et al.  Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. , 2017, Cancer research.